Comparıson of the effıcacy and safety of ısepamıcın and amıkacın ın the treatment of urınary tract ınfectıon ın chıldren
MetadataAfficher la notice complète
Objective: In this study we aimed to compare the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg of body weight twice daily for 10-14 days in children with urinary tract infections (UTI). Methods: One hundred and seventeen patients with urinary tract infection were enrolled in this study. Patients were randomized to treatment with isepamicin or amikacin in a 1:2 ratio. Urinary tract infections were treated with isepamicin (n=42), or amikacin (n=75). Results: The most commonly isolated pathogens were Escherichia coli, Staphylococcus spp., Klebsiella pneumonia, Proteus mirabilis and Enterobacter spp. The overall clinical response rate at the end of treatment was excellent in all treatment groups (93.0/93.4% cured) with no significant differences between isepamicin and amikacin in patients with infections. None of the patients had a life-threatening or severe adverse event that required discontinuation of the drug. Conclusion: Isepamicin was shown to be as effective and as well tolerated as amikacin in the treatment of urinary tract infections in pediatric patients.